Stoneridge Investment Partners LLC Invests $657,000 in Regeneron Pharmaceuticals, Inc. $REGN

Stoneridge Investment Partners LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 861 shares of the biopharmaceutical company’s stock, valued at approximately $657,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Bridgewater Advisors Inc. bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $252,000. USA Financial Formulas bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $1,126,000. BIP Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $325,000. Compound Global Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $62,000. Finally, Summit Global Investments purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $4,680,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent research reports. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Finally, Canaccord Genuity Group lowered their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $793.74.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the transaction, the director directly owned 603 shares in the company, valued at $482,400. This trade represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,400 shares of company stock valued at $1,090,030. Insiders own 6.97% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron is expanding its oncology relationship with Biohaven through a clinical supply agreement to test Biohaven’s BHV-1530 alongside Regeneron’s Libtayo in patients with solid tumors. The combination could strengthen Regeneron’s oncology pipeline if clinical results are favorable. Biohaven-Regeneron Oncology Deal
• Positive Sentiment: Regeneron also entered a strategic research collaboration with Parabilis Medicines to develop antibody-Helicon conjugates. The agreement includes $125 million in upfront consideration and equity investment for Parabilis, with potential milestone payments of up to $2.2 billion plus royalties—highlighting Regeneron’s efforts to broaden its technology base and future pipeline. Parabilis Medicines-Regeneron Collaboration
• Neutral Sentiment: Coverage highlights Regeneron’s exposure to GLP-1-related growth opportunities beyond the leading weight-loss drug makers, although the article provides limited new company-specific financial information. GLP-1 Demand and Regeneron
• Neutral Sentiment: Director Kathryn Guarini sold $320,000 of REGN stock under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance, it is a limited indicator of management’s current outlook.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron concerning alleged disclosures about the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, and the continuing legal notices may keep investor attention focused on potential litigation costs, disclosure risks and weakness in the oncology program. The lead-plaintiff deadline is September 14, 2026. Regeneron Class Action Lawsuit

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $803.48 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11. The firm has a market capitalization of $82.73 billion, a P/E ratio of 19.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.22. The company’s 50-day moving average is $675.79 and its 200 day moving average is $714.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter last year, the firm earned $12.81 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.